VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2022 | New treatments for migraine: who, what, and when?

Jessica Ailani, MD, MedStar Georgetown University Hospital, Georgetown, Washington, DC, outlines new treatments for migraine. Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies are a category of preventative and acute treatments for migraine that have revolutionized the migraine treatment paradigm. CGRP-targeted small molecules, known as gepants, have also recently come to market for prevention and acute use in adults, without the problem of medication overuse headache. Growing evidence supports the use of gepants as early as possible after symptom onset for optimal efficacy; treatment strategies can focus on treating patients earlier, rather than preventing medication overuse headache. Dr Ailani mentions new treatments targeting delta and kappa opioid receptors, pituitary adenylate cyclase-activating polypeptide, and other receptors for pain management. Dr Ailani highlights the importance of dialogue between clinicians and patients about future targets under investigation, as research into new treatments for migraine continues. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.